Skip to content
DataLookout
Menu

TLX101-PxNCT07931261

[18F]FET PET for Differentiating Tumor Progression vs Treatment-Related Changes in Brain Metastases

StatusNot Yet Recruiting
PhasePhase 3
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 1 version: 1 with changes below.

  1. Study First Submitted

Endpoints

Primary

Patient-Level Mean Dice Similarity Coefficient for Lesion Spatial Agreement Between Reduced-Dose and Full-Dose [18F]FET PET Images
Timeframe: From Day 1 through Day 2 (±1 day) follow-up
Sensitivity of [18F]FET PET for Distinguishing Tumor Progression From Treatment-Related Changes Compared With CSOT
Timeframe: From baseline Day 1 through CSOT determination (approximately 2-3 months).

Secondary (11)

Number of Participants With Adverse Events Following Administration of 740 MBq [18F]FET
Inter-Reader Agreement for [18F]FET PET Classification at the Optimized Dose
Lesion-Level Sensitivity of [18F]FET PET for Distinguishing Tumor Progression From Treatment-Related Changes
Sensitivity of [18F]FET PET Compared With Histopathologic Confirmation
Positive Predictive Value of [18F]FET PET for Tumor Progression Compared With CSOT
Show 6 moreShow less
Negative Predictive Value of [18F]FET PET for Tumor Progression Compared With CSOT
Maximum Standardized Uptake Value (SUVmax) of [18F]FET PET Lesions
Mean Standardized Uptake Value (SUVmean) of [18F]FET PET Lesions
Maximum Tumor-to-Brain Ratio (TBRmax) of [18F]FET PET Lesions
Mean Tumor-to-Brain Ratio (TBRmean) of [18F]FET PET Lesions
Number of Participants With Treatment-Emergent Adverse Events (TEAEs) at the Optimized Dose

Arms and interventions

Arm Group Label: [18F]FET PET ImagingExperimental

Drugs: Floretyrosine F 18 ([18F]FET)